Clearside Biomedical (CLSDQ) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
24 Dec, 2025Executive summary
Achieved FDA alignment on pivotal phase III program for CLS-AX in wet AMD following positive phase II-B results, confirming protocol design and endpoints.
Suprachoroidal delivery platform validated by partners, with approvals in Australia and Singapore and regulatory review in China for Arcatus (XIPERE).
Multiple global phase III trials planned or ongoing with partners in diabetic retinopathy, choroidal melanoma, DME, gene therapy, and ocular oncology.
Internal pipeline expansion includes small molecule candidates for geographic atrophy and other ophthalmic indications.
Appointed Tony Gibney as Chair of the Board, bringing significant biotech and business development experience.
Financial highlights
Cash and cash equivalents totaled $20.0 million as of December 31, 2024, sufficient to fund operations into Q4 2025.
Q4 2024 license and other revenue was $0.3M, down from $6.3M in Q4 2023, due to prior year milestone payments.
Q4 2024 net loss was $7.3M ($0.10/share) vs. $4.8M ($0.08/share) in Q4 2023; full year 2024 net loss was $34.4M ($0.47/share) vs. $32.5M ($0.53/share) in 2023.
R&D expenses for Q4 2024 were $4.2M, down from $6.3M in Q4 2023; full year R&D was $18.6M, down from $20.8M.
Outlook and guidance
Actively pursuing funding options for the CLS-AX phase III program, including potential partnerships.
Targeting initiation of phase III trial in the second half of the year, contingent on securing funding.
Pipeline expansion opportunities identified in geographic atrophy, diabetic retinopathy, and diabetic macular edema.
Latest events from Clearside Biomedical
- Suprachoroidal delivery platform advances with strong clinical data and key late Q3 2024 milestones.CLSDQ
Status Update3 Feb 2026 - CLS-AX maintained vision, reduced injections by 84%, and showed strong safety in wet AMD.CLSDQ
Study Result19 Jan 2026 - CLS-AX met Phase 2b endpoints; Q3 net loss narrowed, funding secured into Q3 2025.CLSDQ
Q3 202414 Jan 2026 - Flexible, safe suprachoroidal dosing in wet AMD sets up broad phase III launch in 2025.CLSDQ
Stifel 2024 Healthcare Conference13 Jan 2026 - CLS-AX advances to phase 3, leveraging flexible dosing and suprachoroidal delivery for wet AMD.CLSDQ
Oppenheimer 35th Annual Healthcare Life Sciences Conference 202524 Dec 2025 - Key votes include director elections, say-on-pay, auditor ratification, and doubling authorized shares.CLSDQ
Proxy Filing2 Dec 2025 - Proxy covers director elections, say-on-pay, auditor ratification, and doubling authorized shares.CLSDQ
Proxy Filing2 Dec 2025 - Vote sought on reverse stock split and share reduction to maintain Nasdaq listing.CLSDQ
Proxy Filing2 Dec 2025 - Vote sought on reverse stock split and share reduction to maintain Nasdaq listing compliance.CLSDQ
Proxy Filing2 Dec 2025